PA
MIRM icon

Profund Advisors’s Mirum Pharmaceuticals MIRM Stock Holding History

Profund Advisors’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.05M Sell
22,183
-4,908
-18% -$462K 0.08% 197
2025
Q4 		$2.14M Buy
27,091
+19,515
+258% +$1.4M 0.07% 202
2025
Q3 		$555K Sell
7,576
-611
-7% -$38.8K 0.02% 478
2025
Q2 		$417K Sell
8,187
-2,815
-26% -$125K 0.02% 529
2025
Q1 		$496K Buy
11,002
+1,820
+20% +$85.8K 0.02% 476
2024
Q4 		$380K Sell
9,182
-7,802
-46% -$325K 0.01% 655
2024
Q3 		$662K Buy
16,984
+3,976
+31% +$159K 0.03% 425
2024
Q2 		$445K Sell
13,008
-27,856
-68% -$730K 0.02% 540
2024
Q1 		$1.03M Buy
40,864
+19,694
+93% +$541K 0.04% 355
2023
Q4 		$625K Sell
21,170
-1,886
-8% -$57.1K 0.03% 447
2023
Q3 		$729K Buy
23,056
+1,940
+9% +$53.1K 0.04% 361
2023
Q2 		$546K Buy
21,116
+5,107
+32% +$136K 0.03% 488
2023
Q1 		$385K Buy
+16,009
New +$365K 0.02% 609

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Profund Advisors's MIRM Position: Q1 2026 in Review

Profund Advisors reduced its Mirum Pharmaceuticals (MIRM) stake by 18% in Q1 2026, selling an estimated $462K and leaving 22,183 shares worth $2.05M. The position accounts for 0.08% of the portfolio, ranked #197.

Profund Advisors first reported a position in MIRM in Q1 2023 and has held it in 13 quarters since. The position peaked at $2.14M in Q4 2025. 311 funds tracked by Wall St. Rank hold MIRM as of Q1 2026.

  • Profund Advisors held 22,183 shares of Mirum Pharmaceuticals worth $2.05M as of Q1 2026.
  • Profund Advisors sold 4,908 Mirum Pharmaceuticals shares in Q1 2026, an estimated $462K.
  • Mirum Pharmaceuticals made up 0.08% of Profund Advisors's portfolio in Q1 2026, its #197 holding.
  • Profund Advisors first reported a position in Mirum Pharmaceuticals in Q1 2023 and has held it in 13 quarters since.
  • Profund Advisors's Mirum Pharmaceuticals position peaked at $2.14M in Q4 2025.
  • 311 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q1 2026.

Based on Profund Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.